ENOVEnovis Corporation
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.
Priced for ~6% a year FCF growth. The price demands less than its three-year revenue growth of 12% a year, expectations look modest.
Expensive vs its own history: P/E 109.7 vs a 21.7 median over 20 quarters (+406% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ENOV's price assumes
Enovis Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.55× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 5.0%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +5.6%
Growth the price implies · The price pays for +5.6% free cash flow growth a year for a decade; revenue has grown +12% a year over the last three.
- Price / book
- 0.86
Price / book · today's price, trailing year to Jul 3, 2026
Details›
- Price / booktoday's price, trailing year to Jul 3, 2026
- 0.86
- EV / EBIToperating margin −45%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jul 3, 2026
- 1.11
- Free cash flow, trailing twelve months
- $64M
- Market capitalisation
- $1.27B
- 3-year revenue growth
- +12%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.